About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Bio-Tech Medicine Proves to be Attractive for TCG Lifesciences

by Kathy Jones on February 18, 2012 at 5:27 PM
Font : A-A+

 Bio-Tech Medicine Proves to be Attractive for TCG Lifesciences

A top company official has confirmed that contract research company TCG Lifesciences will foray into the field of bio-tech medicine in the next two years.

"We are a chemistry based drug research company but we plan to venture in the filed of bio-tech medicines in the two years. The bio-tech segment is an emerging market which has been witnessing explosive growth," company managing director Swapan Bhattacharya said here.

Advertisement

"Most of the drug companies are mainly focused in the field of chemistry based medicines, but we think bio-tech is a challenging sector and we are preparing ourselves to enter it," he said.

The company which provides contract research services along with clinical research and laboratory informatics also announced the nomination of a pre-clinical development candidate (candidate) under a R&D collaboration it entered with pharma giant Pfizer Inc. in 2009.
Advertisement

"The candidate is a small molecule new chemical entity developed by us. We have now handed over it to Pfizer which undertake the further research in developing the new molecule into a drug," Bhattacharya said about the 'candidate'.

The new molecule has been developed by a team of 40 scientists in two years. The new component has been tested on animals by the company and has '15 percent of probability to become a drug'.

"Discovery of a new drug can be said to be almost an impossible job. Millions of molecules and compounds are tested before selecting one final molecule which is the candidate. The probability of a candidate becoming a new medicine is very low and requires extensive research. The average cost research incurred on a successful drug is anything between $1.5 million to $2 million," added Bhattacharya.

The company also ruled out floating initial public offering (IPO) in the next few years saying they will go for it only 'when the time is right'.

Promoted by Purnendu Chatterjee and TCG Lifesciences Mauritius Limited with operations in the UK and the US and India, it had in 2007 filed its draft red herring prospectus (DRHP) with the Securities & Exchange Board of India (SEBI) to enter the capital market with its initial public offering of equity shares.

But later it had backed out citing poor market conditions.

Source: IANS
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
Obesity in Teens Make Inroads into Early Atrial Fibrillation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity 

Most Popular on Medindia

Indian Medical Journals Sanatogen The Essence of Yoga Calculate Ideal Weight for Infants Daily Calorie Requirements Pregnancy Confirmation Calculator Noscaphene (Noscapine) Diaphragmatic Hernia Turmeric Powder - Health Benefits, Uses & Side Effects Sinopril (2mg) (Lacidipine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Bio-Tech Medicine Proves to be Attractive for TCG Lifesciences Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests